Vosoritide
![A: Chondrocyte with constitutionally active FGFR3 that down-regulates its development via the MAPK/ERK pathwayB: Vosoritide (BMN 111) blocks this mechanism by binding to the atrial natriuretic peptide receptor B (NPR-B), which subsequently inhibits the MAPK/ERK pathway at the RAF-1 protein.[3]](/Images/godic/202502/20/Vosoritide_mechanism3652.png")
Vosoritide (INN, codenamed BMN-111) is an experimental drug for the treatment of achondroplasia, the most common cause of dwarfism. It is being developed by BioMarin Pharmaceutical and, being the only available causal treatment for this condition, has orphan drug status in the US as well as Europe. As of September 2015, it is in Phase II clinical trials.